Introduction {#sec1-1744806917727917}
============

Chronic pain stems, in part, from an acquired and maintained pathologic sensitization of the dorsal root ganglion (DRG)---spinal cord network. Microarray experiments revealed that sensitization is maintained by sequential waves of gene regulation.^[@bibr1-1744806917727917][@bibr2-1744806917727917]--[@bibr3-1744806917727917]^ Those can impact up to ∼400 genes at a time across a broad spectrum of gene categories, including genes controlling the transcriptional, homeostatic, metabolic, oxidative, protein turnover, trafficking, structural, and communicative states of neurons and glia.^[@bibr1-1744806917727917],[@bibr4-1744806917727917][@bibr5-1744806917727917][@bibr6-1744806917727917][@bibr7-1744806917727917][@bibr8-1744806917727917][@bibr9-1744806917727917][@bibr10-1744806917727917][@bibr11-1744806917727917][@bibr12-1744806917727917][@bibr13-1744806917727917][@bibr14-1744806917727917]--[@bibr15-1744806917727917]^ Dynamically, these expression changes are launched early on by immediate-early transcription factors like early growth factor 1 (EGR1) following an injury and maintained over time by delayed transcription factor networks.^[@bibr16-1744806917727917][@bibr17-1744806917727917]--[@bibr18-1744806917727917]^

Transcription factors directly regulate gene expression, with a single factor regulating the expression of many genes. As such, they represent therapeutic targets with the unique opportunity to simultaneously influence the activity of a high number of genes supporting nociception and influence the long-term course of pain. From a therapeutic prospective, transcription factors can be inhibited by DNA decoys or synthetic double-stranded oligonucleotides that mimic their binding sites on the genome ([Figure 1](#fig1-1744806917727917){ref-type="fig"}). In a prior study, we demonstrated that locally blocking EGR1 activity with an EGR1-specific decoy named AYX1 around the time of an injury prevents the development of long-term pain in rats.^[@bibr18-1744806917727917]^ AYX1 is currently under clinical development (clinicaltrial.gov identifier: NCT02807428). Figure 1.Illustration of DNA decoy action in chronic pain treatment. In a chronic pain state (a), TFs involved in the maintenance of neuronal sensitization bind to specific DNA sequences (TF binding site) on the genome of DRG and spinal cord cells and upregulate or downregulate (pathologic nociception regulation) hundreds of genes (sensitization-related genes). As a result, the genomic status of those cells is shifted toward a pathologic set of gene regulations that are responsible for the maintenance of neuronal sensitization and chronic pain (transcriptomes associated with long-term neuronal sensitization). DNA decoys (green) are synthetic, double-stranded oligonucleotides that mimic the binding sites of their TF target on the genome. The local intrathecal administration of specific DNA decoys (b) can prevent the binding of TF to their binding sites on the genome and interrupt the maintenance of the transcriptomes associated with long-term neuronal sensitization, resetting gene regulation toward a normal transcriptome and a normal neuronal sensitivity. TF: transcription factor.

We hypothesized that a brief inhibition of select delayed transcription factors maintaining the stability of transcriptomes associated with pathologic nociception could reduce pain for long periods of time. An underlying assumption was that once those transcriptomes are destabilized, they are unlikely to spontaneously reinitiate because their occurrence depends on earlier transcriptional waves that have resolved in mature pain states. To test this hypothesis, we designed 35 decoys against single factors or family of factors with the potential to be involved in the maintenance of pathologic nociception. A screening method was implemented to test the decoys in vivo for their capacity to reduce mechanical hypersensitivity in the spared nerve injury (SNI) model of chronic neuropathic pain. The SNI model was chosen for its well-characterized neuropathic pain features and prior demonstration with AYX1 that it can be sensitive to an intrathecal decoy treatment.^[@bibr18-1744806917727917]^ In the light of a high number of decoys to test, screening throughput and animal use considerations, the decoy attrition strategy relied on initially detecting potential efficacy in small groups of animals and assessing accuracy and reproducibility of those effects by their independent reproduction through multiple screening phases. Ultimately, efficacy reproduced through the screening was confirmed in larger groups of animals. Out of the screen, only two decoys produced a significant and long-term reduction in mechanical hypersensitivity, both targeting the Kruppel-like factors (KLFs) family. Iterative in vivo*--*in vitro testing cycles identified the specific KLF factors and decoy binding behaviors associated with each decoy's activity. AYX2 was developed using this knowledge as a drug candidate with the potential to provide long-term reduction of chronic pain in patients with a single administration.

Methods {#sec2-1744806917727917}
=======

Decoys and vehicles {#sec3-1744806917727917}
-------------------

Decoys were designed at Adynxx, except for *KLF reference decoys 1* and *2*, which were selected from the literature (supplemental Table 1).^[@bibr19-1744806917727917],[@bibr20-1744806917727917]^ Sense and antisense strands of each decoy were manufactured by Invitrogen (CA), resuspended in Tris- and calcium-based vehicle formulations, and hybridized at room temperature.

Enzyme-linked immunosorbent assay {#sec4-1744806917727917}
---------------------------------

Decoy binding to KLFs was measured using a customized version of a commercial Enzyme-linked immunosorbent assay (ELISA) kit (Affymetrix, CA). Briefly, 12.8 pmoles of KLF biotin-decoy probe were incubated with 15 µg of HELA nuclear protein extracts for KLF1-6, KLF8-14, and KLF16-17 detection (catalogue \# 36010, Active motif, CA) and HEK290 extracts for KLF15 detection (catalogue \# 36033, Active motif, CA). For KLF7 detection, 0.5 and 1 µg of a recombinant human KLF7 protein was utilized (Novus, CO). The probe--protein mix was processed following the kit's instructions and the quantity of captured KLF measured with an antibody-based colorimetric detection in a microplate reader (OD~450~ nm). Primary antibodies were commercial antibodies validated for specificity by suppliers and characterized for ELISA or assays detecting the native, human form of their target (e.g., gel shift). They are listed in supplemental Table 2. The secondary antibody conjugated to horseradish peroxidase was provided in the ELISA kit (dilution 1:200). The experimental conditions for assay linearity, specificity, and sensitivity were determined using *KLF decoy 1*, the most efficacious KLF decoy identified during the initial in vivo screening, to the human form of KLF4, a predominant KLF member known to bind the KLF consensus binding sites that were used as a frame to design *KLF decoy 1* in silico. Assay sensitivity was optimized by testing the binding level of a fixed amount of *KLF decoy 1* biotinylated probe incubated in the presence of crossover quantities of nuclear protein extracts and KLF4 primary antibody dilutions. Assay specificity was confirmed by standard controls previously described for transcription factor ELISA^[@bibr18-1744806917727917],[@bibr21-1744806917727917]^: (1) nonspecific, background noise correction using a reaction mix lacking proteins internally for each individual assay and testing condition, (2) binding competition experiments to the *KLF decoy 1* biotin probe with free, nonbiotinylated *KLF decoy 1* competitor, (3) confirmation of binding by positive control decoys *KLF reference decoys 1 and 2*, and (4) confirmation of absence of binding by two complementary mutant, non-KLF binding decoys. The expansion of the assay beyond KLF4 to the other KLFs was performed using the same amount of nuclear proteins extract (except for KFL7, see above) and the primary antibody dilution recommended by the supplier when available or the lowest practical dilution with specificity measured against the binding to a mutant decoy.

Animals {#sec5-1744806917727917}
-------

A total of 229 Sprague Dawley rats (Harlan Industries, Livermore, CA), males, 250--300 g, were used. Animal housing and handling was performed in accordance with the Animal Care and Use Committees guidelines of each testing site. Those committees approved all experiments.

Vehicle and decoy administration {#sec6-1744806917727917}
--------------------------------

Articles were delivered via a bolus, percutaneous 20 µL intrathecal injection at the L5--L6 vertebra level as previously described.^[@bibr18-1744806917727917]^ Throughout the study, decoys were dosed between 50 and 300 nmoles, which is consistent with prior work with AYX1 decoy showing that those doses injected intrathecally in rats are sufficient to produce a pharmacological effect.^[@bibr18-1744806917727917]^

Behavioral testing {#sec7-1744806917727917}
------------------

SNI and chronic constriction injury (CCI) models were performed as described elsewhere.^[@bibr22-1744806917727917][@bibr23-1744806917727917]--[@bibr24-1744806917727917]^ Rats were habituated in cages with mesh wire floors for 1 h before von Frey hairs testing. Calibrated von Frey hairs were applied with the following pseudorandom pattern: 6, 1, 10, 4, 26, 10, and 8 g. For each testing level, von Frey hairs were applied five times consecutively to the hind paw ipsilateral to the injury, and the number of paw withdrawals (0 to 5 per level, 0 to 35 in total) was recorded as a response. The time interval between each testing level for a given rat was at least 3 min.^[@bibr18-1744806917727917]^

Blinding and randomization {#sec8-1744806917727917}
--------------------------

Behavioral experiments were all performed blinded. Each testing site received blinded article vials, and the blinding code was revealed to the testing site and experimenter only after testing was completed and the data received. Data were analyzed independently at Adynxx and at the testing sites, and the analyses were cross-checked. Animal randomization to treatment groups was performed before treatment on the day of the first dosing: animals were distributed in groups so that the mean von Frey responses were close across testing groups, targeting within 15% of each other if values permitted.

Predetermined inclusion and exclusion criteria {#sec9-1744806917727917}
----------------------------------------------

Due to the amount of testing required for this work, appropriate animal model performance and technical bias avoidance were pursued by predetermining the following inclusion/exclusion criteria derived from prior experimental work^[@bibr18-1744806917727917],[@bibr25-1744806917727917]^ instead of using sham groups: (1) threshold for the absence/presence of model-induced hypersensitivity: animals with von Frey values ≤5 on the day of the first dosing were excluded since rats can reach this response level in basal conditions and (2) pain model performance: if the average von Frey values of vehicle-treated rats decreased by 50% or more during the first week following injection, then the entire tested cohort (vehicle- plus decoy-treated animals) was excluded. When they occurred, exclusions are listed in the figure legends, and the number of animals listed per testing conditions reflects the exclusions.

Statistical analysis {#sec10-1744806917727917}
--------------------

Nonparametric Student\'s *t* test was used to analyze individual conditions and whole data distribution comparison between experimental conditions using Microsoft Excel, version 14.4.1. One-way analysis of variance and Dunnett's multiple comparison tests were performed using GraphPad Prism version 7.0 (GraphPad Software, La Jolla, CA, [www.graphpad.com](www.graphpad.com)).

Results {#sec11-1744806917727917}
=======

Decoys efficacy screening in the SNI model {#sec12-1744806917727917}
------------------------------------------

Thirty-five transcription factors or families of transcription factor targets were selected for screening based on their known function in pain or pain-related biological systems, such as inflammation or memory and internal cross-species analysis of selected pain-related gene promoters ([Table 1](#table1-1744806917727917){ref-type="table"}). Table 1.Decoy triplexes and transcription factor targets.Triplex numberScreening decoy numberTranscription factor targetFunctional scopeNameSuperclassClassFamilyDecoy 2EGR1Zinc fingerZn finger -- C2H2Developmental/cell cycle regulatorTLX1Decoy 4Immediate early geneCEBPBasic domainsbZIPCAAT enhancerDecoy 31TCF/SRFBeta scaffoldMADs boxResponders to external signalsDecoy 5CREB/ATFBasic domainsbZIPCREBTLX2Decoy 1Constitutive factorAP1Basic domainsbZIPAP1Decoy 9ETS1/SRF/Elk1Helix-turn-helix/ beta scaffoldTryptophan cluster/MADSETS/responder to external signalsDecoy 26RESTZinc fingerZn finger -- C2H2Developmental/cell cycle regulatorsTLX3Decoy 27Tissue/neuro differentiationRUNXBeta scaffoldRuntRuntDecoy 12HNF1Helix-turn-helixHomeo domainHomeo domainDecoy 6ELf1/POU1F1Helix-turn-helixTryptophan clusterETSTLX4Decoy 7Tissue/neuro differentiationELK1Helix-turn-helixTryptophan clusterETSDecoy 8ELK1/ETS1Helix-turn-helixTryptophan clusterETSDecoy 16KLFsZinc fingerZn finger -- C2H2KLF LikeTLX5Decoy 17Tissue/neuro differentiationKLFsZinc fingerZn finger -- C2H2KLF LikeDecoy 35LEF1Beta scaffoldHMGTCF-1Decoy 18MAFBasic domainbZIPMafTLX6Decoy 19Development/cell differentiationMEF2Beta scaffoldMADs boxRegulator of differentiationDecoy 22NgfmaN/AN/AN/ADecoy 23POU2F1/3F/5FHelix-turn-helixHomeo domainPOU domain factorsTLX7Decoy 24Development/cell differentiationPOU4F1Helix-turn-helixHomeo domainPOU domain factorsDecoy 11GATA1Zinc fingerZn finger -- Cys4GATADecoy 28SP1Zinc fingerZn finger -- C2H2Ubiquitous FactorsTLX8Decoy 33Ubiquitous/broad scopeUSFBasic domainsbHLH-ZIPUbiquitous bHLH-ZIP factorsDecoy 3CACCC-box binding factorsN/AN/AN/ATLX9Decoy 30Transcription machineryTBPBeta-scaffoldTATA-binding proteinsTBPDecoy 21NFYBeta-scaffoldHMGNFYDecoy 34ZFHX3Helix-turn-helixHomeo domainHomeo domain plus zinc finger motifsTLX10Decoy 20Ca^++^ sensitiveNFATBeta scaffoldRHRNFATDecoy 15KCNIP3E2F handN/AN/ADecoy 14IRFHomeo domainTryptophan clusterInterferon-regulating factorsTLX11Decoy 25External signal responsePPAR alphaZinc fingerZn finger -- Cys4Thyroid hormone receptor-like factorsDecoy 13HSFHelix-turn-helixHeat shockHSFDecoy 29MixedSTATBeta scaffoldSTATSTATTLX12Decoy 10ETS1Helix-turn-helixTryptophan clusterETSDecoy 32TEAD1Basic domainbZIPbZIP-PAR[^1] Table 2.Differential KLF binding of decoys.KLFKLFKLFCACCC-boxReferenceReferenceMutantDecoy 1Decoy 2DecoyDecoy 1Decoy 2Decoy 1MemberMnMdSEMMnMdSEMMnMdSEMMnMdSEMMnMdSEMMnMdSEMKFL40.1720.1640.0200.2450.1870.0700.3760.3860.0370.5310.5550.0701.1571.1250.1000.1180.1720.040KFL50.3060.2920.0300.4520.4660.0500.6220.4960.1000.4770.5030.1001.0090.9900.0800.3070.2750.050KFL60.3900.2940.0700.2500.2910.0400.2100.2850.0680.0730.0950.0300.1320.1270.0400.1100.0870.050KFL90.2160.2140.0300.1950.1840.0300.1760.1530.0400.1480.0890.0400.2060.0450.1400.0020.0000.000KFL120.3370.3170.0300.2350.2360.0200.2580.2520.0210.2100.2200.0100.2510.2540.0100.2970.2760.030KFL150.3690.3720.0100.2660.2570.0400.0870.0280.0660.2050.2080.0100.1770.1770.0100.1850.1840.000KFL160.2300.1710.0700.1850.2130.0600.2120.2070.0550.2060.1320.0900.3020.3340.0400.1690.1590.020[^2]

Decoys targeting those factors were designed in silico using response element matrices and binding prediction software (e.g., TESS, TRANSFAC, JASPAR). Decoys were grouped in 11 triplexes and one duplex based on the functionality of their target to increase testing throughput (TLX, [Table 1](#table1-1744806917727917){ref-type="table"}). The screening was structured in three sequential phases of attrition: (1) phase 1: identify triplex/duplex with potential efficacy for reducing mechanical hypersensitivity in the SNI model, (2) phase 2: independent confirmation of their efficacy, and (3) phase 3: identification of the individual decoys that carry efficacy. In each phase, articles were injected once at day 14 (15 in one occurrence) following SNI surgery, at which point mechanical hypersensitivity was developed, and once more within 10 days to increase the reliability of tested outcomes. Due to the high number of decoys to test, phase 1 was performed with *n* = 3 for each triplex/duplex, and the accuracy of effects was pursued via their independent reproduction throughout the screening. This strategy was supported by prior work with the AYX1 decoy showing that meaningful decoy-driven pharmacodynamic effects can be detected with *n* = 3 in the SNI model.^[@bibr18-1744806917727917]^ The triplex/duplex approach introduced the possibility of interactions between the effects of decoys when injected together that could mask the effects decoys could have individually. Therefore, the choice was made in phase 2, while "*n*" increased to 5--6 to only seek for trends of efficacy over using a strict statistical analysis to guide triplex selection. In that context, the criteria to define trends of efficacy in phases 1 and 2 were (1) total von Frey hair responses lower compared to vehicle-treated animals and (2) a numerical reduction of at least 25% from the baseline hypersensitivity measured on day 14 for at least two consecutive time points. Statistical analysis was then performed for individual decoys testing in phase 3. Overall, data normalization was an essential tool of the decoy screening and optimization process that allowed for a sensitive analysis of data across small groups of animals, independent testing and laboratories. The corresponding raw von Frey data are presented in supplemental tables.

In the first phase of the screening, only the effects of TLX1, TLX4, and TLX5 matched our dual selection criteria for efficacy, and their effect was tested for approximately three weeks ([Figure 2(a)](#fig2-1744806917727917){ref-type="fig"}). Figure 2.Effects of the triplex/duplex in the phase 1 of the decoy screening in the SNI model. Decoys' performance relating to the dual efficacy criteria are shown: von Frey values normed on POD 14 values before the first injection (white bars), and von Frey values normed on vehicle values at each tested day (black curves). Blue dashed lines mark the normed threshold value of 1 to assess decoys performance (black curves) against vehicle. Red dashed lines mark the normed threshold value of 0.75 (i.e., 25 % reduction) to assess decoys performance (white bars) against POD14 preinjection von Frey values. von Frey values were normalized individually for each rat, and data are presented as means for each group; corresponding raw von Frey values are presented in supplemental Table 3. The triplexes meeting the predefined criteria of potential efficacy are shown in (a) while the ones that did not are shown in (b). Each triplex contained 100 nmoles of each decoy and the duplex TLX12 contained 150 nmoles of each decoy. Dosing occurred once at day 14 (day 15 for TLX10) and day 17 (day 18 for TLX10); *n* = 3 for each triplex/duplex and *n* = 4 for vehicle. This study was performed at the Stanford University. POD: post-surgery day.

TLX7 and TLX8 showed some potential for efficacy early on, so they were also followed over three weeks, but their effects did not meet our dual criteria at the end ([Figure 2(a)](#fig2-1744806917727917){ref-type="fig"} and ([b](#fig2-1744806917727917){ref-type="fig"})). No trend of effect was suggested by TLX6, TLX9, TLX10, or TLX11 treatments, which illustrates the specificity of the triplex/duplex approach ([Figure 2(b)](#fig2-1744806917727917){ref-type="fig"}). Finally, the effects of TLX2, TLX3 and TLX12 suggested a potential aggravation of mechanical hypersensitivity ([Figure 2(b)](#fig2-1744806917727917){ref-type="fig"}). In the second phase, TLX1 and TLX5 but not TLX4 reproduced efficacy by meeting our dual criteria ([Figure 3(a)](#fig3-1744806917727917){ref-type="fig"}). TLX8, which only met the efficacy criteria against vehicle in phase 1, was also tested here to further assess for the sensitivity of our approach. Consistent with phase 1, it met only one predefined criteria for efficacy but not the two ([Figure 3(a)](#fig3-1744806917727917){ref-type="fig"}). Figure 3.(a) Effects of TLX1, TLX4, TLX5, and TLX8 in the phase 2 of the decoys' screening in the SNI model. Triplexes contained 100 nmoles of each decoy and were dosed once at post-surgery day (POD) 14 and 23. (b) Effect of TLX1 and of its individual decoys tested in parallel in the phase 3 of the screening. *t* test versus vehicle, \**p* \< 0.05, *n* = 5--6 per group. (c) Effect of TLX5 and of its individual decoys tested in parallel in the phase 3 of the screening, *t* test versus vehicle, \**p* \< 0.05, *n* = 3 per group. In all graphs, decoys' performance relating to the dual efficacy criteria are shown: von Frey values normed on POD14 preinjection values are displayed as white bars, and von Frey values normed on vehicle values at each tested day are displayed as black curves. Blue dashed lines mark the normed threshold value of 1 to assess decoys performance (black curves) against vehicle, red dashed lines mark the normed threshold value of 0.75 (i.e., 25 % reduction) to assess decoys performance (white bars) against POD14 preinjection von Frey values. von Frey values were normalized individually for each rat, and data are presented as means for each group; corresponding raw von Frey values are presented in supplemental Table 3. In (b) and (c) sections, TLX1 and TLX5 contained 100 nmoles of each decoy, individual decoys were dosed at 200 nmoles and injections occurred once at day 14 and 17. Inclusion/exclusion based on predetermined criteria: two rats in (a) and three rats in (b) did not develop hypersensitivity following surgery, with POD14 von Frey values ≤5 and were excluded. The experiment in (c) was performed in two sequential cohorts of three animals per group with equal representation of testing conditions. All vehicle-treated animals of the first cohort showed a reduction of von Frey values in the 50% range or below, with an average of 59% reduction between POD14 and POD20 leading to the exclusion of that cohort (vehicle- plus decoy-treated animals). This study was performed at the Stanford University. KLF: Kruppel-like transcription factor; POD: post-surgery day.

TLX1 and TLX5 were then carried into the final phase of the screening to evaluate the efficacy of their respective individual decoys. Two hundred nanomoles of each decoy were injected versus 100 nmoles in their respective triplex (i.e., maximal dose due to solubility and dosing volume limits as each triplex contained three different molecular entities). Individual decoys from TLX1 only demonstrated a modest efficacy that was short-lived and that could not be amplified by a second injection ([Figure 3(b)](#fig3-1744806917727917){ref-type="fig"}). From TLX5, the two decoys binding KLF factors, *KLF decoys 1* and *2*, produced a robust and long-lasting reduction in mechanical hypersensitivity that was maintained numerically over controls until the hypersensitivity from the model started to resolve ∼5 weeks after injections ([Figure 3(c)](#fig3-1744806917727917){ref-type="fig"}). In contrast, the *LEF1 decoy 35* showed a limited efficacy that was numerically lower than the triplex efficacy ([Figure 3(c)](#fig3-1744806917727917){ref-type="fig"}). Interestingly, TLX8, which showed potential efficacy during the screening, contains a *CACCC-box decoy*, which has a consensus site for the SP/KLF family different from *KLF decoy 1* and *2*. These results suggested differential KLF binding patterns for the KLF decoys and raised the question of which KLFs are involved in chronic pain. Raw von Frey data for each group and testing phase of the screening are presented in supplemental Table 3. Table 3.Binding profiles of KLF decoy 1 and 2 variants selected for in vivo testing.KLF decoy 1 variantsKLF decoy 2 variantsVariant decoy name1.6.21.6.51.92.12.52.9Variant decoy size (bp)251822152421Size reduction relative to original decoy (%)32%51%41%48%17%28%Mean relative binding efficiency148%127%134%168%141%128%Binding efficiencyKLF6Mean102%65%135%94%125%146%relative to original decoySEM9%17%41%19%14%27%KLF9Mean193%184%128%285%168%127%SEM10%40%8%116%14%15%KLF15Mean150%131%138%125%130%111%SEM5%10%16%25%5%7%[^3]

Decoy KLF binding patterns {#sec13-1744806917727917}
--------------------------

The KLF family includes 17 members, each recognizing a range of DNA sequences.^[@bibr26-1744806917727917],[@bibr27-1744806917727917]^ *KLF decoys 1* and *2* were designed in silico. To decipher their actual KLF binding pattern, a KLF ELISA assay was developed to measure their binding activity against the human forms of the 17 family members ([Figure 4(a)--(c)](#fig4-1744806917727917){ref-type="fig"}). Binding activities of *KLF decoys 1* and *2* were compared to (1) the *CACCC-box decoy* from TLX8, (2) two independent *KLF reference decoys* containing complementary versions of the KLF consensus-binding site selected from the literature,^[@bibr19-1744806917727917],[@bibr20-1744806917727917]^ and (3) to negative control-mutant decoys.^[@bibr18-1744806917727917]^ Positive binding was found for at least one decoy to KLF4, KLF5, KLF6, KLF7, KLF9, KLF12, KLF15, and KLF16 ([Table 2](#table2-1744806917727917){ref-type="table"}). No relevant binding was detected for the other KLFs under our testing conditions. Importantly, decoys all presented different KLF binding patterns ([Figure 4(d)](#fig4-1744806917727917){ref-type="fig"} and [Table 2](#table2-1744806917727917){ref-type="table"}), consistent with the different efficacy profiles observed for the KLF decoys in vivo. Figure 4.(a) KLF ELISA linearity and sensitivity. Increasing amounts of Hela nuclear protein extracts were incubated with a fixed amount of *KLF decoy 1* biotinylated probe (12.5 µmoles) and either 1:1000 (square) or 1:200 (black and white circles, two separate experiments) dilution of a specific KLF4 antibody. The signal produced by the 1:200 dilution plateaus after 15 µg of protein. Regressions of the linear signal portion for each antibody dilution are shown as dotted line (*R*^2 ^= 0.87 and 0.91 and 1:1000 and 1:200, respectively). (b) KLF ELISA specificity control 1. The specificity of KLF binding is illustrated by the positive binding of *reference decoys 1* and *2* to KLF4 and the lack of binding to KLF4 of two different mutant decoys lacking KLF binding sites. (c) KLF ELISA specificity control 2. Specificity of the assay was further demonstrated by the inhibition of KLF4 binding to the biotinylated *KLF decoy 1* probe in the presence of increasing amount of free *KLF decoy 1* competitor. This study was performed at Adynxx. (d) Decoys' KLF binding patterns. Pie graph representation of the proportionate binding of each specific KLF relative to the total binding to all bound KLFs for the corresponding decoy. Binding data significantly different from the binding level of mutant decoy 1 (*p* ≤ 0.05), or with a trend of statistical significance (*p* ≤ 0.1), were used to generate the graphs (see [Table 2](#table2-1744806917727917){ref-type="table"}), *n* ≥ 5. This study was performed at Adynxx. (e) Effect of decoys with differential KLF binding patterns in the spared nerve injury (SNI) model. Mean + SEM values of normalized total responses to repetitive von Frey hair application for animals groups treated with vehicle (white triangle), *KLF reference decoy 1* (black triangle), *KLF reference decoy 2* (black circle), *CACCC-box decoy* (black square), *KLF decoy 1* (X mark) and *2* (white square) are displayed. Normalization of von Frey hair responses was performed for each rat individually against its preinjection value measured on post-surgery day 14, and the corresponding raw von Frey values are presented in supplemental Table 4. Articles were injected intrathecally once on day 14 and 17 (arrows). Testing of *KLF decoys 1* and *2* and *reference decoy 1*, which presented the strongest activity level, was pursued until von Frey values started to resolve from a plateau level toward baseline in the vehicle group (day 48). Preinjection data before day 14 are combined across groups, 200 nmoles of each decoy or vehicle were injected once at days 14 and 17 (arrows), *t* test versus vehicle: \**p* ≤ 0.05, data distribution over the testing periods: ANOVA, all groups: *p* \< 0.0001, Dunnett's multiple comparison test against vehicle: *p* \< 0.0001 for all groups except for *KLF ref 2* (*p* = 0.53), *n* = 5 per group. This study was performed at AfaSci, Inc. (f). Range of effect of the KLF decoys in the SNI model. Mean + SEM values of response for each individual von Frey hair out of five stimulations from the day of the first injection until the last day of testing for each decoy plotted from the experiment displayed in (e) above, ref = reference, *t* test versus vehicle, \**p* \< 0.05, ANOVA, for all groups at each hair level from 6 to 26 g: *p* \< 0.05, Dunnett's multiple comparison test against vehicle: ‡*p* \< 0.05. KLF: Kruppel-like transcription factor; VF: von Frey hair.

KLF decoys with combined binding to KLF6, KLF9, and KLF15 treat chronic pain {#sec14-1744806917727917}
----------------------------------------------------------------------------

To identify which KLFs are associated to a decoy\'s efficacy for reducing pain and if they differ with the type of injury, *KLF decoy 1* and *2* were tested in parallel to the *CACCC-box decoy* and to the two *KLF reference decoys* in the SNI (i.e., nerve transection) and CCI models (i.e., nerve ligature). Two hundred nanomoles of each decoy were injected at day 14 and 17, similar to the phase 3 of the screen. In the SNI model, *KLF decoy 1* and *KLF reference 1* both produced a maximum mechanical hypersensitivity reduction of ∼70%, and their effect was observed until hypersensitivity was resolving in controls ([Figure 4(e)](#fig4-1744806917727917){ref-type="fig"} and supplemental Table 4). *KLF decoy 2* produced efficacy in a similar range in terms of amplitude and duration, although numerically lower. The *CACCC-box decoy* produced an intermediate level of efficacy that resolved earlier; therefore, its testing was not pursued beyond day 31. On the other end, *KLF reference decoy 2* was not effective. When examining the sensitivity of the von Frey hairs affected by the efficacious decoys, the entire range was reduced from light (1 g) to strong mechanical stimuli (26 g) that elicit a paw withdrawal response even in the absence of an injury ([Figure 4(f)](#fig4-1744806917727917){ref-type="fig"}). In the CCI model, the decoys also produced an array of efficacy patterns, *KLF decoys 1* and *2* being most efficacious (supplemental Table 4).

The combined analysis of decoy's KLF binding pattern and efficacy profiles in the SNI model highlights the following: (1) KLF9 binding appears to be a prerequisite to efficacy since *KLF reference decoy 2* is the only decoy to not bind KLF9 and to not show efficacy and (2) KLF15 inhibition appears necessary for long-term efficacy and robust pain reduction as the *CACCC-box decoy*, the active decoy with the lowest and shortest-lived efficacy, does not bind to KLF15 while the other active decoys do. Similar cross-analysis in the CCI model, in which *KLF decoys 1* and *2* showed a meaningful efficacy and the *CACCC-box decoy* an intermediary efficacy level, suggests that (1) an appropriate level of inhibition of KLF9 is necessary but not sufficient for a robust efficacy since it is the common denominator between *KLF decoys 1, 2* and the *CACCC-box decoy* which present different efficacy levels (the fact that reference *decoy 1* also inhibits KLF9 suggests that another factor it binds could interfere with its activity), and (2) KLF6 inhibition is required for a robust and sustained efficacy since only *KLF decoys 1* and *2* have significant binding to KLF6. Those data suggest that KLF6, KLF9, and KLF15 cooperate to maintain chronic pain across the tested injuries, KLF9 and KLF15 in the SNI and KLF9 and KLF6 in the CCI models.

AYX2 sequence development {#sec15-1744806917727917}
-------------------------

*KLF decoys 1* and *2* possess a unique ability to reduce pain by inhibiting KLF6, KLF9, and KLF15 activities. Those were selected as a basis to generate the sequence of a therapeutic decoy candidate for the treatment of chronic pain. The objectives for generating such sequence were to (1) reduce the sequence size below 25 bp (*KLF decoy 1* and *2* are 37 and 29-bp long, respectively) to achieve appropriate solubility for clinical dosing (e.g., 110 mg/mL similar to AYX1 decoy, ClinicalTrials.gov identifier NCT02807428) and (2) maintain binding efficiency (i.e., binding activity normalized by decoy size) to KLF6, KLF9, and KLF15 as decoy size decreases. The optimization process was conducted in two steps: (1) a first set of sequences was generated and tested to identify families of sequences with the potential to meet the targeted decoy features and then (2) a novel set of sequences was derived from the lead sequence families initially identified to further improve sequence features.

The binding of each decoy to KLF6, KLF9, and KLF15 was measured in duplicate and in parallel to *KLF decoys 1* and *2* using the KLF ELISA described above. When a sequence of interest was identified, its binding was confirmed independently once or twice more. Over 30 variant sequences were generated through this process by fusion, and orientation of the two KLF binding sites present in *KLF decoys 1* and *2*, as well as modifying the sequence and size of their 5' and 3' flanking sites. A variety of binding profiles were produced by those sequences, and six decoys (1.6.2, 1.6.5, 1.9, 2.1, 2.5, and 2.9) were selected as best matching the predetermined criteria ([Table 3](#table3-1744806917727917){ref-type="table"}).

The effect of a single administration of each of these decoys was tested in parallel to *KLF decoys 1* and *2* in the SNI and CCI models. Decoys or vehicle were injected on post-surgery day 14, and their effects were measured up to day 31, a time point sufficient to discriminate different efficacy patterns. Results highlighted a spectrum of decoy efficacy patterns in terms of amplitude and duration of pain relief across the two models ([Figure 5(a)](#fig5-1744806917727917){ref-type="fig"}--([c](#fig5-1744806917727917){ref-type="fig"}) and supplemental Table 5). *Decoy 1.6.5* was selected as AYX2 because it has (1) the same efficacy as *KLF decoy 1* in the SNI model and the highest combined efficacy across the SNI and CCI models ([Figure 5(a)](#fig5-1744806917727917){ref-type="fig"}--([c](#fig5-1744806917727917){ref-type="fig"})) and (2) a short size (18 bp) while maintaining the binding parameters of its parent *KLF decoy 1* (37 bp; [Figure 6(a)](#fig6-1744806917727917){ref-type="fig"}). The significant and long-lasting effects of a single administration of ascending doses of AYX2 were further confirmed in independent experiments in the SNI and CCI models ([Figure 6(b)](#fig6-1744806917727917){ref-type="fig"}--([e](#fig6-1744806917727917){ref-type="fig"})). Figure 5.(a) Effect of variants of *KLF decoy 1* in the SNI model. Mean + SEM values of normalized total responses to repetitive von Frey hairs application for animal groups treated with vehicle (triangle), *KLF decoy 1* (X mark), *1.6.5* (white circle), *1.6.2* (square), and *1.9* (black circle) decoys are displayed. Normalization of von Frey hair responses was performed for each rat individually against its preinjection value measured on post-surgery day 14, and the corresponding raw von Frey values are presented in supplemental Table 5. Articles were injected intrathecally once on post-surgery day 14 (arrow); Preinjection data before day 14 are combined across groups, *t* test versus vehicle: \**p* ≤ 0.05, data distribution over the testing period: ANOVA, all groups: *p* \< 0.0001, Dunnett's multiple comparisons test against vehicle: *p* \< 0.05 for all comparisons except for decoy 1.9, *n* = 4 per group. This study was performed at AfaSci, Inc. (b) Range of effect of the variants of *KLF decoy 1* in the SNI model. Mean + SEM values of response for each individual von Frey hair out of five stimulations from the day of injection until the last day of testing for each decoy plotted from the experiment displayed in (a) above, ref = reference, *t* test versus vehicle, \**p* \< 0.05, ANOVA for all groups at each hair level from 6 to 26 g: *p* \< 0.05, Dunnett's multiple comparison test against vehicle: ‡*p* \< 0.05. (c) Efficacy pattern of KLF decoys in the SNI and CCI pain models. Mean efficacy values for each decoy tested in the SNI and CCI models are plotted. Efficacy is calculated as the percentage of reduction of normalized von Frey hair response values compared to vehicle during the entire testing period (area under the curve) in each study and model, *n* = 4--6 per decoy and model. (d) Linear regression of KLF decoy\'s efficacy in the SNI model in relation to KLF15/KLF9 binding ratio. Efficacy is measured as described in (c) above. When a decoy efficacy was tested in independent studies, the value used for the plot is an average of the efficacy measured across those studies. Similarly, when a decoy binding was repeated throughout several phases of the sequence development process, the value used for the plot is an average of the binding measured across those phases. Each dot represents values of a given decoy, linear regression (red line), coefficient of linear regression *R*^2 ^∼ 0.7. (e) Linear regression of KLF decoy efficacy in the CCI model in relation to KLF6 + KLF9 binding. This plot was constructed using the principles described in (c). Each dot represents values of a given decoy, coefficient of linear regression *R*^2 ^∼ 0.6. Studies included in (c), (d), and (e) were performed at the Stanford University and AfaSci, Inc. CCI: chronic constriction injury; KLF: Kruppel-like transcription factor; SNI: spared nerve injury; VF: von Frey hair. Figure 6.(a) Comparison of AYX2 (white bars) and KLF decoy 1 (black bars) binding features for KLF6, KLF9 and KLF15. Mean + SEM binding efficiency for each KLF (binding level in OD~450~ unit divided by the decoy size in bp) is shown in the graph; *n* ≥ 5. This study was performed at Adynxx, Inc. (b) Effect of ascending AYX2 doses in the SNI model. Mean + SEM values of total responses to repetitive von Frey hair application for groups treated with vehicle (white triangle) or AYX2 50 (black triangle), 100 (X mark), 200 (black circle), or 300 nmoles (white circle) are displayed. In this experiment, the 50-nmole AYX2 dose is considered without effect based on the fact that von Frey responses remain stable following injection and do not increase nor decrease. Articles were injected intrathecally once on day 14 (arrow), *t* test versus vehicle: \**p* ≤ 0.05, data distribution over the testing period: ANOVA, all groups: *p* \< 0.0001, Dunnett's multiple comparisons test against vehicle: *p* \< 0.05 for all comparisons, *n* = 4 per group. (c) Range of effect of increasing dose levels of AYX2 in the SNI model. Mean + SEM values of response for each individual von Frey hair out of five stimulations over the testing period from the day of injection until the last day of testing plotted from the experiment displayed in (b) above, *t* test versus vehicle, \**p* \< 0.05, ANOVA for all groups at each hair level from 4 to 26 g: *p* \< 0.0005, Dunnett's multiple comparison test: ‡*p* \< 0.05. (d) Effect of ascending AYX2 dose levels in the CCI model. Mean + SEM values of total responses to repetitive von Frey testing for animals groups treated with vehicle (white triangle) or AYX2 200 (black circle) or 300 nmoles (white circle) are displayed. Articles were injected intrathecally once on day 14 (arrow), *t* test versus vehicle: \**p* ≤ 0.05, data distribution over the testing period: ANOVA, all groups: *p* \< 0.0001, Dunnett's multiple comparisons test against vehicle: *p* \< 0.05 for all comparisons, *n* = 4 per group. (e) Range of effect of increasing dose levels of AYX2 in the CCI model. Mean + SEM values of response for each individual von Frey hair out of 5 stimulations over the testing period from the day of injection until the last day of testing plotted from the experiment displayed in (d) above, *t* test versus vehicle, \**p* \< 0.05, ANOVA, for all groups at each hair level from 6 to 26 g: *p* \< 0.05, Dunnett's multiple comparison test against vehicle: ‡*p* \< 0.05. Studies presented parts (b)--(e) were performed at AfaSci, Inc. KLF: Kruppel-like transcription factor; VF: von Frey hair.

Functional relationships associated with KLF6, KLF9, and KLF15 binding {#sec16-1744806917727917}
----------------------------------------------------------------------

Binding to KLF9 appears central to a decoy efficacy, in association with KLF15 binding in the SNI model and with KLF6 binding in the CCI model. To understand the functional relationship between the bindings of each KLF pair, a detailed meta-analysis of in vivo and in vitro datasets generated during this body of work was conducted. It was hypothesized that a decoy efficacy could be driven by either the absolute binding level to its targets or by a ratio of binding to its targets. To test this, the average efficacy level of decoys in each pain model was analyzed as a potential linear function of KLF binding features. The analyses suggested that in the SNI model, the efficacy of a decoy is associated with its KLF15/KLF9 binding ratio ([Figure 5(d)](#fig5-1744806917727917){ref-type="fig"}): If the binding level of KLF15 is similar to the binding level of KLF9 (i.e., KLF15/KLF9 ∼0.9), the decoy has no effect.If the ratio of KLF15/KLF9 binding is unbalanced, a decoy efficacy increases as a linear function of the KLF15/KLF9 binding ratio (i.e., the more KLF15 binding over KLF9, the higher the efficacy, *R*^2 ^∼ 0.7).

In the CCI model, the efficacy of a decoy appears in part correlated with its combined binding capacity to KLF6 + KLF9 ([Figure 5(e)](#fig5-1744806917727917){ref-type="fig"}): The sole binding level to KLF6 (linear regression coefficient *R*^2 ^∼ 0.3), KLF9 (*R*^2 ^∼ 0.4), or KLF15 (*R*^2 ^∼ 0.3) is not sufficient to explain efficacy.Combining KLF15 binding level to either KLF6 or KLF9 binding does not alter their respective linear regression coefficient (i.e., KLF6 *R*^2 ^∼ 0.3 ∼ KLF6 + KLF15 *R*^2 ^∼ 0.3; KLF9 *R*^2 ^∼ 0.4 ∼ KLF9 + KLF15 *R*^2 ^∼ 0.4), suggesting that KLF15 binding does not play a significant role in this type of pain.Efficacy appears to be a linear function of the combined binding of KLF6 + KLF9 (*R*^2^ of 1/(KLF6 + KLF9) ∼0.6): the more the binding, the higher the efficacy. Considering the value level of the regression coefficient, it is conceivable that other factors potentially independent of binding activities, such as stability or cellular uptake influence a decoy's activity. Collectively, this meta-analysis shows that the relationships between KLF9 and KLF15 or KLF9 and KLF6 are different and work independent of each other.

Discussion {#sec17-1744806917727917}
==========

Effects of intrathecal AYX2 and binding to KLF6, KLF9, and KLF15 {#sec18-1744806917727917}
----------------------------------------------------------------

Pain is a dynamic state maintained at the genomic level by dynamic transcriptomes.^[@bibr1-1744806917727917],[@bibr28-1744806917727917]^ A group of transcription factors with the potential to control these transcriptomes was selected based on their known functions and gene promoter's analysis. The impartial screening of decoys designed against those factors identified two decoys that bind to KLF6, KLF9, and KLF15 that significantly reduced chronic pain following a single administration in the SNI and CCI models of pain.

Based on prior work using repeat von Frey testing,^[@bibr18-1744806917727917],[@bibr25-1744806917727917]^ the magnitude of von Frey responses at the time of the decoy treatments reflected a fully developed mechanical hypersensitization and nociceptive state. In that context, KLF decoys produced up to ∼60%--70% reduction in mechanical hypersensitivity compared to controls, and the effect lasted until hypersensitivity was resolving in controls. Based on the correlation between ELISA binding data and in vivo efficacy levels analyses, KLF9 binding appears to be the central component of the trio of KLFs bound by the decoys, in association with KLF15 binding to treat pain in the SNI model and with KLF6 binding in the CCI model. The functional relationships between KLF9 binding and binding to the two other KLFs are not of similar nature, suggesting that different transcriptional mechanics underlie pain maintenance in the two pain models. This observation is consistent with head-to-head microarray comparison of spinal cord gene regulations showing that the amount and type of genes regulated are principally different in the SNI and CCI models.^[@bibr29-1744806917727917]^

AYX2 was developed as a KLF decoy drug candidate with a short size capable to achieve a solubility level compatible with clinical use. Prior pharmacodynamic, pharmacokinetic, and metabolism studies in rats with AYX1 showed that a short decoy, unprotected from metabolism, acts locally in the DRG and/or the spinal cord tissues following an intrathecal administration.^[@bibr18-1744806917727917],[@bibr25-1744806917727917],[@bibr30-1744806917727917]^ Further, this work showed that AYX1 rapidly penetrates the DRG and spinal cord following administration and that cell uptake likely occurs in a nonspecific fashion in both neurons and glial cells via endocytic mechanisms.^[@bibr23-1744806917727917]^ Considering the doses used with AYX2 are similar to AYX1, that both decoys are of comparable size and unprotected toward metabolism, an analogous local tissue and cells distribution is anticipated. Independent work in mice shows that KLF6, KLF9, and/or KLF15 are expressed in the DRG and/or the spinal cord in basal or pathologic nociceptive conditions.^[@bibr31-1744806917727917][@bibr32-1744806917727917]--[@bibr33-1744806917727917]^ Determining whether AYX2 site of action is primarily the DRG, the spinal cord or both in the SNI and CCI models would constitute a next step in the characterization of AYX2 mechanism of action.

Potential roles of KLF6, KLF9, and KLF15 in nociception {#sec19-1744806917727917}
-------------------------------------------------------

Uncovering the potential functions of KLF6, KLF9, and KLF15 in the DRG and/or spinal cord in relation to nociception requires experimental determination and would be a direct expansion of the work presented here. However, hypotheses can be drawn based on the known roles of KLF6, KLF9, and KLF15 in the central nervous system, and we propose in the section below mechanisms that could be at play in relation to AYX2 efficacy.

The nociceptive system functions through long-term potentiation and memory mechanisms similar to the hippocampus.^[@bibr34-1744806917727917]^ Studies of the hippocampus in KLF9 knockout versus wild-type mice showed that KLF9 is expressed in neurons and required for neurogenesis-dependent synaptogenesis in adults.^[@bibr35-1744806917727917]^ Further, KLF9 expression is induced by neuronal activity and regulates genes involved in synaptic plasticity (e.g., Lin7b, pentraxin-2, Nav1.3, Ca~v~3.1, KChip4, KCNA4).^[@bibr36-1744806917727917][@bibr37-1744806917727917][@bibr38-1744806917727917][@bibr39-1744806917727917][@bibr40-1744806917727917][@bibr41-1744806917727917]--[@bibr42-1744806917727917]^ It is possible that KLF9 controls the transcriptomes maintaining synaptic structural rearrangement and hyperexcitability following injury in the DRG and spinal cord, two landmark mechanisms of chronic pain. While KLF15 can be expressed in neurons, KLF15 is sufficient to induce an astrocyte phenotype and appears to be mainly expressed in GFAP-positive astrocytes in the adult spinal cord.^[@bibr32-1744806917727917]^ The fact that AYX2 efficacy is concurrent with KLF9 and KLF15 binding at a ratio different from ∼1 in the SNI model suggests that the physiological output of KLF9 and KLF15 functions as a ratio of their respective activities. Similar mechanisms have been illustrated in endocrine systems, where KLF9 and KLF15 are implicated in feed forward loops and synergistic transcriptional mechanisms.^[@bibr43-1744806917727917]^ Thus an appropriate ratio of transcriptional activity of KLF9 in neurons and KLF15 in astrocytes may be required in the DRG--spinal cord network for the two cell types to efficiently interact and coordinate the perpetuation of chronic pain. This may be achieved by locally maintaining high activity levels of bi- (pre- and post-synaptic neurons) and tri- (including astrocytes) partite synapses. Such intercellular cross talk would be consistent with KLF physiology, as illustrated by KLF4 and KLF5 which coordinate epithelial cell proliferation while being expressed in different cell types.^[@bibr26-1744806917727917]^ In such context, an hypothesis is that AYX2 treatment could restore the ratio of KLF15 and KLF9 activities in neurons and astrocytes to a baseline level, disrupting the pathologic state of communication between those cells required for high synaptic activity and chronic pain.

In the CCI model, our data suggest that AYX2 activity is driven by total binding to KLF6 plus KLF9, independent of the ratio of binding, which would indicate that KLF6 and KLF9 roles are redundant for maintaining chronic pain. Similar functional redundancy has been demonstrated between KLF6 and KLF7 which can compensate for each other to drive neurite outgrowth.^[@bibr44-1744806917727917]^ Further, multiple KLFs can act as a network to regulate common intracellular pathways.^[@bibr43-1744806917727917]^ Since KLF9 is involved in synaptogenesis, one can envision KLF6 and KLF9 both maintaining the synaptic changes required for neuronal sensitization and pain in the DRG--spinal cord network. Interestingly, a side-by-side electrophysiological study of the DRG--spinal cord connectivity in the SNI and CCI models revealed "divergent plasticity" mechanisms of excitatory synaptic transmission in the two models.^[@bibr45-1744806917727917]^ This data is consistent with KLF9 function in synaptic plasticity and suggests that KLF9 and KLF15 on one hand and KLF9 and KLF6 on the other hand build distinct modalities of plasticity in the two models.

KLF6, KLF9, and KLF15 in rodents and human {#sec20-1744806917727917}
------------------------------------------

KLF6, KLF9, and KLF15 are well-conserved ortholog proteins with 94%, 97%, and 84% protein identity, respectively, between rat and human forms. Further, an almost complete conservation is found within their zinc finger DNA binding sites with sequence identities ranging from 97% to 100% across the two species (NCBI accession numbers: NP_113830/NP_001291, NP_476559/NP_001197, AAH89782/NP_054798).

This structural conservation appears to correlate, at least in the systems that have been studied below, to a conservation of function between rodents and human. For instance, experiments in mice and in human endothelial cells showed that KLF6 promotes vascular remodeling following an injury in both species.^[@bibr46-1744806917727917]^ Head-to-head study in mice and human primary hepatocytes showed that KLF9 was induced by the triiodothyronine hormone and controlled the downstream hepatocytes proliferation and differentiation response.^[@bibr47-1744806917727917]^ As for KLF15, it is upregulated by glucocorticoids in human and mouse airway smooth muscles and acts as a regulator of airway function, illustrating conservation of both function and regulation.^[@bibr48-1744806917727917],[@bibr49-1744806917727917]^ This combined information on the conservation of KLF structure, regulation, and function supports the potential translation of AYX2 drug candidate effects from rats to human and highlights KLF6, KLF9, and KLF15 as novel targets for the treatment of pain.

Conclusions {#sec21-1744806917727917}
===========

This study shows that KLF decoys binding to KLF6, KLF9, and KLF15 transcription factors can alleviate mechanical hypersensitivity in the SNI and CCI rat models of chronic neuropathic pain. The correlation of in vitro decoy binding data with in vivo efficacy suggests KLF9 cooperates in different fashions with KLF6 and KLF15 depending on the pain etiology, which is consistent with the modus operandi of this large family of integrated transcription factors. AYX2 is an 18-bp long DNA decoy developed specifically to bind and inhibit KLF6, KLF9, and KLF15 locally in the DRG spinal cord network to produce large and long-lasting relief of mechanical hypersensitivity following a single intrathecal injection. This data support AYX2 therapeutic potential for treating chronic pain syndromes and constitutes the basis for characterizing further the roles of the KLF family in nociception.

The authors thank Drs Tony Yaksh (University of California San Diego), William K. Schmidt (NorthStar Consulting, LLC), George Miljanich (In memoriam, SiteOne Therapeutics, Inc.), Rick Orr, William Martin, Kim Herbert, and Dina Gonzalez from Adynxx, Inc. for their great support and guidance in the accomplishment of this work.

Author Contributions {#sec22-1744806917727917}
====================

Julien Mamet, Donald Manning, and Scott Harris designed and monitored this work. Michael Klukinov, David Yeomans, Conrado Pascual, and Simon Xie performed pharmacology experiments. Julien Mamet also designed the decoys described in the study and performed the ELISA experiments. Brad Taylor and Renee Donahue guided pharmacology study designs. All authors read and approved the final manuscript.

Declaration of Conflicting Interests {#sec23-1744806917727917}
====================================

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Julien Mamet, Donald Manning, and Scott Harris are Adynxx employees and shareholders. David Yeomans and Brad Taylor are Adynxx consultants and/or shareholders.

Funding {#sec24-1744806917727917}
=======

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Adynxx, Inc.

[^1]: bZIP: basic leucine zipper; bHLH-ZIP: helix-loop-helix/leucine zipper factors; Screening decoy 16: KLF decoy 1; Screening decoy 17: KLF decoy 2; Screening decoy 3: CACCC-box decoy; neuro: neurological tissue; N/A: not applicable.

[^2]: Mean (Mn), median (Md), and SEM binding OD~450~ values (KLF ELISA) for each decoy to KLF4, KLF5, KLF6, KLF9, KLF12, KLF15, and KLF16 are presented in the table. Student's *t* test versus corresponding mutant decoy binding values: no highlight = statistically significant (*p* ≤ 0.05), blue highlight = statistical trend (*p* ≤ 0.1), gray highlight = not statistically significant (*p* \> 0.1). A hint of binding for KLF7 was detected for *KLF decoy 2* and *reference decoy 2*; however, data could not be compared to the other KLF as it required using a recombinant version of the human KLF7 protein versus whole nuclear extracts for the other KLFs.

[^3]: Relative binding efficiency is calculated as the binding of a decoy for a given KLF normalized by its sequence size and the binding efficiency of the decoy it derives from. Mean relative binding efficiency relates to the combined relative binding efficiency of KLF6, KLF9, and KLF15; *n* = 4 for each testing condition.
